Tech Company Financing Transactions
Proclara Biosciences Funding Round
Proclara Biosciences closed a $10 million Series D financing round on 1/14/2015. Investors included private investors.
Transaction Overview
Company Name
Announced On
1/14/2015
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the Company's lead drug candidate, NPT088, into clinical studies by the end of this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
125 Cambridgepark Dr. 301
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Not Recorded
Overview
Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Suzanne Bruhn
Chief Medical Officer
David Michelson
Chief Scientific Officer
Richard Fisher
VP - Manufacturing
Jason Wright
VP - Operations
Kelly Magnuson
VP - R & D
Rajaraman Krishnan
VP - R & D
Jonathan Levenson
VP - Regulatory Affairs
Roxanne Bales
Browse more venture capital transactions:
Prev: 1/14/2015: My Digital Shield venture capital transaction
Next: 1/14/2015: Curemark venture capital transaction
Share this article
News on VC Transactions
We report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs